<DOC>
	<DOCNO>NCT02737462</DOCNO>
	<brief_summary>&lt; Part I - Phase I trial &gt; The phase I clinical trial identify MTD ( Maximum Tolerated Dose ) DLT ( Dose Limiting Toxicity ) CG200745 PPA . Initial dose CG200745 PPA 150 mg/m^2 , extend 225 mg/m^2 , 300 mg/m^2 reduce 75 mg/m^2 base result cohort 3 subject per dose level . Based 3+3 dose escalation study design , CG200745 PPA administer four different cohort accord dose level . Each cohort consist 3 6 subject . &lt; Part II - Phase II trial &gt; In phase II clinical trial , subject administer dose identify recommend dose base result Phase I study . The whole one cycle consist 28 day , phase I . The entire treatment period 6 cycle tumor assessment evaluate every 2 cycle .</brief_summary>
	<brief_title>Phase 1/2 Study CG200745 PPA Myelodysplastic Syndrome</brief_title>
	<detailed_description>&lt; Part I - Phase I trial &gt; The phase I clinical trial identify MTD DLT CG200745 PPA . Initial dose CG200745 PPA 150 mg/m^2 , extend 225 mg/m^2 , 300 mg/m^2 reduce 75 mg/m^2 base result cohort 3 subject per dose level . Based 3+3 dose escalation study design , CG200745 PPA administer four different cohort accord dose level . Each cohort consist 3 6 subject . - Dose Level -1 : CG200745 PPA 75 mg/m^2 x 5 ( 375 mg/m^2/cycle ) / -50 % - Dose Level 1 : CG200745 PPA 150 mg/m^2 x 5 ( 750 mg/m^2/cycle ) / initial base dose - Dose Level 2 : CG200745 PPA 225 mg/m^2 x 5 ( 1,125 mg/m^2/cycle ) / 50 % - Dose Level 3 : CG200745 PPA 300 mg/m^2 x 5 ( 1,500 mg/m^2/cycle ) / 33 % &lt; Part II - Phase II trial &gt; In phase II clinical trial , subject administer dose identify recommend dose base result Phase I study . The whole one cycle consist 28 day , phase I . The entire treatment period 6 cycle tumor assessment evaluate every 2 cycle .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Ages : 20 year Patient MDS accord FrenchAmericanBritish ( FAB ) classification Patients fail respond prior hypomethylating agent ( 5azacytidine , decitabine ) Eastern Cooperative Oncology Group ( ECOG ) performance status : 02 Adequate renal hepatic function Total serum bilirubin ≤ 3 x Upper Limit Normal ( ULN ) ( except case increase unconjugated bilirubin ) Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , Alkaline phosphatase ( ALP ) &lt; 3 x ULN Calculated Glomerular Filtration Rate ( GFR ) ≥ 50 Modification Diet Renal Disease ( MDRD ) GFR ( mL/min/1.73m2 ) ( female ) : 186 x ( serum creatinine concentration ) 1.154 x ( age ) 0.203 x 0.742 ( female ) Fertile patient , except postmenopausal patient ( menstruation least 2 year ) proof surgical sterility , must use effective contraception 3 month completion withdrawal study . Negative pregnancy test Patient understand overall procedure requirement study Peripheral bone marrow blast : &gt; 30 % Less 4 week since major surgery radiotherapy Patient clinically meaningful relevant , active Central Nerve System ( CNS ) disorder Patient active liver disease Patient HIV positive Hypersensitivity study drug similar substance drug Prior Histone Deacetylase ( HDAC ) inhibitor therapy Less 4 week since hypomethylating agent cytotoxic drug therapy Less 4 week since immunosuppressive drug therapy Patient participate another clinical trial within past 4 week Patient severe disease : Severe cardiovascular disease ( severe unstable angina , congestive heart failure , myocardial infarction within past 1 year , uncontrolled hypertension uncontrolled arrhythmia ) Neurological psychiatric disorder Active uncontrolled infection Any disease may interfere interpretation study result ( accord judgment investigator ) Pregnancy lactate Patient consider appropriate study accord judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>